* Dementia correlates to decreased cognitive function, and Behavioral and Psychological Symptoms of Dementia (Neuropsychiatric symptom, BPSD) as well. * Neuropsychiatric symptom attributes important role for mortality, mortality, and cause to enter nursing home. * Study on neuropsychiatric symptom in patients with Parkinson's disease has not been thorough yet, and there even has not been any study done on this in Korea yet. * The investigators will study prevalence of neuropsychiatric symptom in PDD patients and burden of caregiver.
* It is well recognized that the importance of non-motor symptoms of Parkinson's disease during its progression and many patients are suffering from this. The deterioration of cognitive function is especially known as a crucial prognostic factor. According to recently released cohort study, majority of patients go through dementia in advanced Parkinson's disease. * Dementia correlates to decreased cognitive function, and Behavioral and Psychological Symptoms of Dementia (Neuropsychiatric symptom, BPSD) as well. Neuropsychiatric symptom composed of abnormal behavior and psychological symptoms: abnormal behaviors include combativeness, wandering, agitation, akathisia, inappropriate sexual behavior, following caregiver, shouting, cursing, insomnia and binge eating while psychological symptoms include anxiety, depression, hallucination, and illusion. Neuropsychiatric symptom is evaluated depending on information given by caregivers, and symptoms are likely to be temporary or changing constantly. Two thirds of patients is found to have neuropsychiatric symptom when they are diagnosed as dementia, 65 % in nursing home and 70\~90% in advanced dementia states. Neuropsychiatric symptom attributes important role for mortality, mortality, and cause to enter nursing home. * Besides, neuropsychiatric symptom also plays important part as care-giver burden. It gives heavier burden on caregiver rather than on patients, and increases depression and anxiety of caregivers. Specific correlation with patient's neuropsychiatric symptom to burden of caregiver is known as agitation, depression, aggression, repetitive behavior, anxiety, and disinhibition. There are, however, various results related to race, region, subjects, and investigator. * Study on neuropsychiatric symptom in patients with Parkinson's disease dementia has not been thorough yet, and there even has not been any study done on this in Korea yet. * The investigators will study prevalence of neuropsychiatric symptom in PDD patients and burden of caregiver.
Study Type
OBSERVATIONAL
Enrollment
48
The Catholic University of Korea, Yonsei University
Seoul, Seoul, South Korea
Neuropsychiatric inventory
It collects information on symptoms during the past month in 10 domains-delusions, hallucinations, agitation, depression, anxiety, elation, apathy, disinhibition, irritability, and aberrant motor behaviors-using a structured interview with a knowledgeable informant.
Time frame: Baseline
Follow-up neuropsychiatric inventory
The change of prevalence of neuropsychiatric symptoms after choline esterase inhibitor treatment.
Time frame: Six months after choline esterase inhibitor treatment
Care-giver burden_baseline
The burden of caregiver determined by Burden Interview(BI) and Caregiver Burden inventory(CBI)
Time frame: Baseline
Care-giver burden change
The burden change of caregiver using the same scale (BI and CBI).
Time frame: Six months after choline esterase inhibitor treatment
Motor function_baseline
Hoehn and Yahr stage and Unified Parkinson's disease rating scale, part 3
Time frame: Baseline
Motor function_change
Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale
Time frame: Six months after choline esterase inhibitor treatment
General cognitive function_baseline
The Korean version of mini mental status examination, clinical dementia rating, Barthel and Instrumental ADL
Time frame: Baseline
General cognitive function_change
The Korean version of mini mental status examination, clinical dementia rating, Barthel and Instrumental ADL
Time frame: Six months after choline esterase inhibitor treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.